metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-r...
Journal Information
Vol. 44. Issue 3.
Pages 164-171 (April 2020)
Share
Share
Download PDF
More article options
Visits
7
Vol. 44. Issue 3.
Pages 164-171 (April 2020)
Original article
Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone
Papel del índice neutrófilo/linfocito en pacientes con cáncer de próstata resistente a castración metastásicos tratados en primera línea con abiraterona
Visits
7
D. Nieblas-Toscano
Corresponding author
nieblasdavinia@gmail.com

Corresponding author.
, A.J. Arenas-Bonilla, J.F. Flores-Martín, F. Gutiérrez-Tejero, C. Velarde-Muñoz, C.I. Ramos-Alaminos, M.C. Salas-Moreno, R. Galisteo-Moya, J. Moreno-Jiménez
Servicio de Urología, Complejo Hospitalario de Jaén, Jaén, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (2)
Table 1. Baseline characteristics of patients with mCRPC treated with abiraterone according to <or> 3 neutrophil/lymphocyte index. </or>
Table 2. Comparative of other studies.
Show moreShow less
Abstract
Introduction

In patients with prostate cancer, high NLR seems to be associated with worse survival. Abiraterone acetate (AA) is a new generation hormonal treatment that has shown to increase PFS and OS in mCRPC.

Material and methods

Retrospective analysis of patients treated with AA in our center (December 2012-September 2018). We analyzed the association of the NLR ( <o≥3) before="" and="" after="" 6="" months="" of="" treatment="" with="" psa="" response,="" pfs,="" os,="" hormone="" sensitivity="" prior="" to="" aa="" (<or=""> 12 months). </o≥3)>

Results

We have treated 56 patients with a median age of 82 (62–94), of which 22 (39%) had NLR ≥ 3 before treatment.

There is a statistically significant association between the NLR prior to treatment <3 and PSA response, OR = 9444, p = 0.001, and there was no association with the NLR at 6 months of treatment.

Statistically significant differences were found between the groups of NLR < and> 3 prior to treatment with abiraterone in PFS with 15 months of median vs 9 and p = 0.008, and in OS with 20 months vs 9 with p = 0.014.

With respect to the determination of NLR at 6 months, there are no differences in the survival curves between both groups.

There are significant differences between the NLR prior to treatment according to the length of hormone sensitivity (p = 0.026).

Conclusions

Our results suggest that NLR could provide relevant information and could act as an early and accessible prognostic marker in patients with mCRPC in first line treatment with Abiraterone.

Keywords:
Abiraterone
Prostate cancer
Castration resistance
Neutrophil/lymphocyte ratio
Resumen
Introducción

En pacientes con cáncer de próstata un NLR elevado parece asociarse a una peor supervivencia. Abiraterona es un tratamiento hormonal de nueva generación que ha aumentado SLP y SG en CPRCm.

Material y métodos

Análisis retrospectivo de pacientes tratados con AA en nuestro centro (diciembre 2012–septiembre 2018). Analizamos la asociación del NLR ( <o≥3) previo="" y="" a="" los="" 6="" meses="" de="" tratamiento="" con="" la="" respuesta="" del="" psa,="" slp,="" sg,="" hormonosensibilidad="" previa="" aa="" (<o=""> 12 meses). </o≥3)>

Resultados

Hemos tratado 56 pacientes con una mediana de edad de 82 (62-94), de los cuales 22 pacientes (39%) presentan NLR ≥ 3 previo al tratamiento.

Existe una asociación estadísticamente significativa entre el NLR previo al tratamiento <3 y la respuesta del PSA, OR = 9,444, p = 0.001, no existiendo esa asociación con el NLR a los 6 meses de tratamiento.

Se encontraron diferencias estadísticamente significativas entre los grupos de NLR < y > 3 previo al tratamiento con abiraterona en SLP con 15 meses de mediana vs 9 y una p = 0,008 y en SG con 20 meses vs 9 con una p = 0,014.

Con respecto a la determinación de NLR a los 6 meses no existe diferencias en las curvas de supervivencia entre ambos grupos.

Existen diferencias significativas entre el NLR previo al tratamiento según la duración del tiempo hasta la resistencia a castración p = 0,026.

Conclusiones

Nuestros resultados sugieren que el NLR podría aportarnos información trascendente y ser constituido un marcador pronóstico temprano y accesible en los pacientes CPRCm en tratamiento en primera línea con Abiraterona.

Palabras clave:
Abiraterona
Cáncer de próstata
Resistencia castración
Indice neutrófilo/linfocito

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.acuroe.2021.10.005
No mostrar más